These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8857077)
1. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Bonnabry P; Leemann T; Dayer P Eur J Clin Pharmacol; 1996; 49(4):305-8. PubMed ID: 8857077 [TBL] [Abstract][Full Text] [Related]
2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
3. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Bourrié M; Meunier V; Berger Y; Fabre G Drug Metab Dispos; 1999 Feb; 27(2):288-96. PubMed ID: 9929518 [TBL] [Abstract][Full Text] [Related]
4. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Transon C; Lecoeur S; Leemann T; Beaune P; Dayer P Eur J Clin Pharmacol; 1996; 51(1):79-85. PubMed ID: 8880056 [TBL] [Abstract][Full Text] [Related]
5. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. Gentile DM; Verhoeven CH; Shimada T; Back DJ J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390 [TBL] [Abstract][Full Text] [Related]
7. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015 [TBL] [Abstract][Full Text] [Related]
8. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Transon C; Leemann T; Dayer P Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Leemann T; Transon C; Dayer P Life Sci; 1993; 52(1):29-34. PubMed ID: 8417277 [TBL] [Abstract][Full Text] [Related]
10. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160 [TBL] [Abstract][Full Text] [Related]
11. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation. Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614 [TBL] [Abstract][Full Text] [Related]
12. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Yamazaki H; Inoue K; Shimada T Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436 [TBL] [Abstract][Full Text] [Related]
13. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. Butler AM; Murray M J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313 [TBL] [Abstract][Full Text] [Related]
14. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203 [TBL] [Abstract][Full Text] [Related]
15. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Hamman MA; Thompson GA; Hall SD Biochem Pharmacol; 1997 Jul; 54(1):33-41. PubMed ID: 9296349 [TBL] [Abstract][Full Text] [Related]
16. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Bort R; Macé K; Boobis A; Gómez-Lechón MJ; Pfeifer A; Castell J Biochem Pharmacol; 1999 Sep; 58(5):787-96. PubMed ID: 10449188 [TBL] [Abstract][Full Text] [Related]
17. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587 [TBL] [Abstract][Full Text] [Related]
18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228 [TBL] [Abstract][Full Text] [Related]
19. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Court MH; Duan SX; Hesse LM; Venkatakrishnan K; Greenblatt DJ Anesthesiology; 2001 Jan; 94(1):110-9. PubMed ID: 11135730 [TBL] [Abstract][Full Text] [Related]
20. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Crewe HK; Ellis SW; Lennard MS; Tucker GT Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]